Toralizumab

From Self-sufficiency
Revision as of 14:55, 29 July 2010 by PotatoBot (Talk) (Stub sorting and placement of stub template(s))

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Toralizumab
Monoclonal antibody
Type Whole antibody
Source Template:Infobox drug/mab source
Target CD40 ligand
Identifiers
CAS Number 252662-47-8
ATC code none
Chemical data
Molar mass 148,426 Daltons
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Toralizumab (IDEC 131) was a humanized monoclonal antibody and an immunosuppressive drug. Possible indications included treatment of antibody-mediated disorders (immune thrombocytopenic purpura, lupus nephritis, rheumatoid arthritis), T-cell-mediated diseases (multiple sclerosis, Crohn's disease, and transplantations such as solid organ transplantation, pancreatic islet cell transplantation, and corneal transplantation), and B-cell malignancies such as CLL/small lymphocytic lymphoma, follicular cell lymphoma grade I or II, marginal zone lymphoma, mantle cell lymphoma, MALT lymphoma, Waldenstrom's macroglobulinemia, monocytoid B-cell lymphoma; relapsed/refractory Hodgkin's disease).[1]

In Phase II clinical trials regarding multiple sclerosis and Crohn's disease, thromboembolisms occurred in at least three patients. A causal connection could not be proven, but since the same adverse effects were seen in trials with a similar antibody (hu5C8), the trials were halted.[2]

The drug was developed by IDEC Pharmaceuticals Corporation.

References

  1. ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Toralizumab, American Medical Association.
  2. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
Intracellular
(initiation)
Macrolides/
other IL-2 inhibitors
TNF-α inhibitor
Intracellular
(reception)
Extracellular
Serum target
(noncellular)
Cellular target
Unsorted
-cept (Fusion)
"-tuzu-" (tumor)
"-lizu-" (immune system)
"-bazu-" (bacterial)
"-cizu-" (cardiovascular)
"-nezu-"/"-neuzu-" (nervous system)
"-toxazu-" (toxin as target)
"-vizu-" (viral)
"-kizu-" (interleukin as target)
"-anibizu-" (angiogenesis inhibitor)
†Undergoing clinical trials. §Never marketed.


40x30px This monoclonal antibody-related article is a stub. You can help ssf by expanding it.
40px This antineoplastic or immunomodulatory drug article is a stub. You can help ssf by expanding it.
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Toralizumab&oldid=23086"